|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Cardiology, University of Connecticut School of Medicine, Connecticut, United States
2 Dept of Cardiology, University of Connecticut Health Center, Farmington, Connecticut, United States; Cardiology, University of Connecticut School of Medicine, Connecticut, United States
3 Natick; US Army Research Institute of Environmental Medicine, Massachusetts, United States
4 Genetics, University of connecticut Health Center, Connecticut, United States
5 Molecular Recognition Section, NIDDK, NIH, Bethesda, Maryland, United States
6 Dept of Cardiology, University of Connecticut Health Center, Farmington, Connecticut, United States
* To whom correspondence should be addressed. E-mail: bliang{at}uchc.edu.
Although adenosine exerts cardio- and vasculoprotective effects, the roles and signaling mechanisms of different adenosine receptors in mediating skeletal muscle protection are not well understood. We used a mouse hindlimb ischemia/reperfusion model to delineate the function of three adenosine receptor subtypes. Adenosine A3 receptor selective agonist Cl-IBMECA (0.07 mg/kg, intraperitoneal) reduced skeletal muscle injury with a significant decrease in both Evans blue dye staining (5.4% ± 2.6%, n = 8 mice vs. vehicle-treated 28% ± 6%, n = 7 mice, P < 0.05) and serum creatine kinase level (1840 U/L ± 910 U/L, n = 13 vs. vehicle-treated 12,600 U/L ± 3300 U/L, n = 14, P < 0.05), an effect that was selectively blocked by an A3 receptor antagonist MRS1191 (0.05 mg/kg). The A1 receptor agonist CCPA (0.05 mg/kg) also exerted a cytoprotective effect, which was selectively blocked by the A1 antagonist DPCPX (0.2 mg/kg). The A2A receptor agonist CGS21680 (0.07 mg/kg)-induced decrease in skeletal muscle injury was selectively blocked by the A2A antagonist SCH 442416 (0.017 mg/kg). The protection induced by the A3 receptor was abrogated in phospholipase C
2/
3 null mice, but the protection mediated by the A1 or A2A receptor remained unaffected in these animals. The adenosine A3 receptor is a novel cytoprotective receptor that signals selectively via phospholipase C
and represents a new target for ameliorating skeletal muscle injury.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |